目次

Table of Content

1. Research Methodology

2. Introduction To MCL1 Inhibitors
2.1 MCL1 As A Therapeutic Target
2.2 Role of MCL1 in Cancer

3. MCL1 Inhibitors - Mechanism of Action
3.1 Indirect Inhibition of MCL1
3.2 Direct Inhibition of MCL1

4. Role of MCL1 and Clinical Innovation by Indication
4.1 Hematological Malignancies
4.1.1 Leukemia
4.1.2 Lymphoma
4.1.3 Multiple Myeloma
4.2 Solid Cancers
4.2.1 Breast cancer
4.2.2 Lung Cancer
4.2.3 Melanoma
4.2.4 Colorectal cancer
4.3 Viral Infections

5. Global MCL1 Inhibitor Drug Market Opportunity Outlook
5.1 Current Clinical Research Landscape
5.2 Future Commercialization Opportunities

6. Global MCL1 Inhibitor Drugs Clinical Trials Overview
6.1 By Company
6.2 By Country
6.3 By Indication
6.4 By Patient Segment
6.5 By Phase

7. MCL1 Inhibitors Clinical Trials Insight By Company, Country, Indication and Phase
7.1 Preclinical
7.2 Phase I
7.3 Phase I/II
7.4 Phase II

8. Competitive Landscape
8.1 Abbvie
8.2 Amgen
8.3 Anji Pharma
8.4 Ascentage Pharma
8.5 Broad Institute
8.6 Cyclacel Pharmaceuticals
8.7 Gilead Sciences
8.8 Novartis
8.9 Servier
8.10 Sirnaomics

List of Figures
Figure 4-1: MIK665 Phase I Study (NCT04702425) - Initiation and Completion Year
Figure 4-2: AZD5991 Phase I/II Study (NCT03013998) - Initiation and Completion Year
Figure 4-3: GFH009 Phase I/II Study (NCT04588922) - Initiation and Completion Year
Figure 6-1: Global - MCL1 Inhibitor Drugs Trials By Company (Numbers), 2024
Figure 6-2: Global - MCL1 Inhibitor Drugs Trials By Country (Numbers), 2024
Figure 6-3: Global - MCL1 Inhibitor Drugs Trials By Indication (Numbers), 2024
Figure 6-4: Global - MCL1 Inhibitor Drugs Trials by Patient Segment (Numbers), 2024
Figure 6-5: Global - MCL1 Inhibitor Drugs Trials By Phase (Numbers), 2024